Our Pricing

Mounjaro vs Wegovy UK: Which Weight Loss Injection Is Right for You?

When comparing mounjaro vs wegovy uk options, both prescription weight loss injections have transformed obesity treatment, but they work differently and deliver distinct results. Mounjaro (tirzepatide) targets two hormones for appetite control, whilst Wegovy (semaglutide) acts on one — a difference that translates into measurably different weight loss outcomes in clinical trials. Understanding which treatment aligns with your health profile, budget, and weight loss goals requires examining the evidence behind each medication, and that's precisely what this pharmacist-led comparison will help you do.

How Mounjaro vs Wegovy UK Medications Work Differently

The fundamental difference between mounjaro vs wegovy uk treatments lies in their mechanism of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single gut hormone to reduce appetite and slow gastric emptying [1]. Mounjaro, however, is a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, offering a two-pronged approach to metabolic regulation [2].

This dual action means Mounjaro influences insulin secretion, fat metabolism, and energy expenditure more comprehensively than Wegovy. In our clinical experience at Cured Pharmacy, patients often ask whether this translates to better results — and the trial data suggests it does. The SURPASS-2 head-to-head trial directly compared tirzepatide against semaglutide, showing tirzepatide delivered superior weight loss across all doses [2]. However, both medications require gradual dose escalation and work best alongside dietary modification and increased physical activity.

Receptor Targeting: Single vs Dual Agonism

Wegovy's single-receptor approach has proven highly effective — average weight loss in the STEP trials reached 15% of body weight over 68 weeks [1]. Mounjaro's dual-receptor activation, however, achieved up to 22.5% average weight reduction in SURMOUNT trials at the highest dose [2]. Both medications are administered as weekly subcutaneous injections and require ongoing prescriber supervision. At Cured Pharmacy, every prescription follows a comprehensive clinical assessment by our UK-registered prescribers to ensure suitability and safety.

Mounjaro vs Wegovy UK Clinical Trial Results Compared

When evaluating mounjaro vs wegovy uk efficacy, the SURPASS-2 trial provides the gold standard comparison. This 40-week study enrolled 1,879 adults with type 2 diabetes, comparing tirzepatide (5mg, 10mg, and 15mg) directly against semaglutide 1mg [2]. Results showed tirzepatide 15mg achieved an average 5.5kg greater weight loss than semaglutide — a statistically significant and clinically meaningful difference.

For weight management specifically, the SURMOUNT-1 trial demonstrated Mounjaro's potential in adults without diabetes. Participants taking tirzepatide 15mg lost an average of 22.5% body weight over 72 weeks, compared to 2.4% with placebo [3]. Wegovy's STEP 1 trial showed 14.9% average weight loss over 68 weeks versus 2.4% placebo [1]. Both represent substantial improvements over lifestyle modification alone, but the numerical advantage consistently favours tirzepatide in head-to-head and parallel comparisons.

Side Effects: Mounjaro vs Wegovy UK Patient Experiences

The side effect profiles of mounjaro vs wegovy uk treatments overlap considerably, as both are incretin-based therapies affecting gastrointestinal function. The most common adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These typically emerge during dose escalation and diminish over time as the body adapts.

In SURPASS-2, gastrointestinal side effects occurred in 70-80% of tirzepatide participants versus 60-65% with semaglutide, though discontinuation rates remained similar (4-7% across groups) [2]. Importantly, both medications carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans. Our superintendent pharmacist Tarun Kumar emphasises the importance of reporting any persistent neck swelling, hoarseness, or difficulty swallowing during treatment. Both medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Managing Gastrointestinal Symptoms

Most patients find gastrointestinal side effects manageable with simple strategies: eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. The gradual dose titration schedule built into both mounjaro vs wegovy uk treatment protocols helps minimise these effects. At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey, with advice tailored to your individual response and any side effects you experience.

Dosing Schedules: Mounjaro vs Wegovy UK Titration Protocols

Understanding the dosing progression for mounjaro vs wegovy uk treatments is essential for setting realistic expectations. Wegovy begins at 0.25mg weekly for four weeks, then escalates monthly through 0.5mg, 1mg, and 1.7mg, reaching the maintenance dose of 2.4mg by week 17 [1]. This gradual increase allows your body to adapt whilst minimising gastrointestinal side effects.

Mounjaro follows a similar philosophy but with different increments: starting at 2.5mg weekly for four weeks, then increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg [2]. The higher absolute doses reflect tirzepatide's different receptor binding characteristics — not greater potency per milligram. Both medications are administered via pre-filled injection pens designed for self-administration in the abdomen, thigh, or upper arm. Our clinical team at Cured Pharmacy provides detailed injection technique guidance and ongoing monitoring throughout your dose escalation, ensuring you feel confident and supported at every stage.

Cost Analysis: Mounjaro vs Wegovy UK Pricing at Cured Pharmacy

Price is a significant consideration when comparing mounjaro vs wegovy uk options, as both are premium weight management treatments. At Cured Pharmacy, we guarantee the lowest UK prices with complete transparency — you'll see exact costs before completing your clinical assessment. Wegovy starts from £124.99, whilst Mounjaro begins at £124.99, reflecting differences in manufacturing, licensing, and market positioning.

New patients can access an additional £20 discount on their first order using code Weightlossnew, making these clinically proven treatments more accessible. Unlike some providers, we never hide prices behind consultations or charge separate prescriber fees — what you see is what you pay, including your medication, clinical assessment by a UK-registered prescriber, and discreet home delivery. Both treatments represent a significant investment in your health, but when you consider the clinical trial data showing sustained, substantial weight loss, many patients find the cost justifiable as part of a comprehensive weight management programme overseen by healthcare professionals.

Long-Term Cost Considerations

Weight loss medications like mounjaro vs wegovy uk treatments are typically prescribed for extended periods — often 6-12 months or longer, depending on individual response and goals. Budgeting for ongoing monthly costs is essential. At Cured Pharmacy, we offer subscription options that ensure uninterrupted treatment at the lowest possible price point, with the flexibility to adjust or pause as your needs change. Our clinical team regularly reviews your progress to ensure the treatment remains appropriate and cost-effective for your circumstances.

Which Should You Choose: Mounjaro vs Wegovy UK Decision Framework

Deciding between mounjaro vs wegovy uk treatments isn't purely about efficacy numbers — it involves weighing clinical evidence, side effect tolerance, cost, and individual health factors. If maximising weight loss is your primary goal and budget permits, Mounjaro's superior trial results make it a compelling choice, particularly at higher doses [2][3]. However, Wegovy remains an excellent option with substantial evidence, a slightly better-tolerated side effect profile in some studies, and a lower price point [1].

Certain medical conditions may influence your prescriber's recommendation. Both medications are contraindicated in pregnancy, and both require caution in patients with pancreatitis history, severe gastrointestinal disease, or diabetic retinopathy. Your BMI, weight loss goals, previous medication responses, and budget will all factor into the clinical decision. At Cured Pharmacy, our UK-registered prescribers conduct thorough assessments considering all these variables, ensuring you receive a personalised recommendation rather than a one-size-fits-all approach. Every prescription is subject to clinical approval, and our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing to maintain the highest safety and quality standards.

Starting Your Treatment Journey

Beginning either mounjaro vs wegovy uk treatment is straightforward at Cured Pharmacy. Complete our confidential online clinical assessment in under three minutes, and a UK-registered prescriber will review your information, typically within 24 hours. If approved, your medication is dispensed by our GPhC-registered pharmacy (9012511) and delivered discreetly to your door, often with next-day delivery options. We provide ongoing clinical support, dose adjustment guidance, and prescription renewals throughout your weight loss journey, ensuring you never feel alone in the process.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-218. [accessed 15 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.